Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Oteracil
1. Oteracil
2. 937-13-3
3. 5-azaorotic Acid
4. Allantoxanic Acid
5. 4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazine-2-carboxylic Acid
6. Oteracil [inn]
7. Oxonate
8. 1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazine-2-carboxylic Acid
9. 4,6-dioxo-1h-1,3,5-triazine-2-carboxylic Acid
10. 5vt6420tig
11. Chebi:30863
12. 1,4,5,6-tetrahydro-4,6-dioxo-s-triazine-2-carboxylic Acid
13. Oxc
14. Unii-5vt6420tig
15. Oxonsaure
16. Oxonic-acid
17. 1,3,5-triazine-2-carboxylic Acid, 1,4,5,6-tetrahydro-4,6-dioxo-
18. Oxonic Acid [mi]
19. Oteracil [who-dd]
20. Nciopen2_000442
21. Oteracil [ema Epar]
22. Schembl464773
23. Chembl181932
24. Dtxsid9048358
25. Bcp32168
26. Zinc13514753
27. Akos006272679
28. Am84784
29. Db03209
30. Sb73387
31. Db-079670
32. Dihydroxy-1,3,5-triazine-2-carboxylic Acid
33. Ft-0707227
34. S-triazine-2,4-dione-6-carboxylic Acid
35. Q22075725
36. 1,3,5-triazine-2-carboxylicacid,1,4,5,6-tetrahydro-4,6-dioxo-
37. 4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazine-2-carboxylicacid
38. Oteracil Pound>>5-azaorotic Acid Pound>>4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazine-2-carboxylic Acid
| Molecular Weight | 157.08 g/mol |
|---|---|
| Molecular Formula | C4H3N3O4 |
| XLogP3 | -1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 157.01235559 g/mol |
| Monoisotopic Mass | 157.01235559 g/mol |
| Topological Polar Surface Area | 108 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 269 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Oteracil is used as an adjunct to antineoplastic therapy. When used within the product Teysuno, oteracil is indicated for the treatment of adults with advanced gastric (stomach) cancer when given in combination with cisplatin.
Absorption
After administration of a single dose of 50 mg Teysuno (expressed as tegafur content), median Tmax for Teysuno components tegafur, gimeracil, and oteracil was 0.5, 1.0, and 2.0 hours, respectively.
Route of Elimination
Following a single dose of Teysuno, approximately 3.8% to 4.2% of administered tegafur, 65% to 72% of administered gimeracil, and 3.5% to 3.9% of administered oteracil were excreted unchanged in the urine.
Volume of Distribution
Although no intravenous data are available for Teysuno in humans, the volume of distribution could be roughly estimated from the apparent volume of distribution and urinary excretion data as 16 l/m2, 17 l/m2, and 23 l/m2 for tegafur, gimeracil and oteracil, respectively.
Based on the results of in vitro studies, a part of oteracil is non-enzymatically degraded to 5-azauracil (5-AZU) by gastric fluid, and is then converted to cyanuric acid (CA) in the digestive tract. Only a small amount of oteracil is metabolised in the liver because of its low permeability.
Following a single dose of Teysuno, T1/2 values ranged from 6.7 to 11.3 hours for tegafur, from 3.1 to 4.1 hours for gimeracil, and from 1.8 to 9.5 hours for oteracil.
Oteracil's main role within Teysuno is to reduce the activity of 5-FU within normal gastrointestinal mucosa, and therefore reduce's gastrointestinal toxicity. It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
50
PharmaCompass offers a list of Oteracil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Oteracil manufacturer or Oteracil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Oteracil manufacturer or Oteracil supplier.
PharmaCompass also assists you with knowing the Oteracil API Price utilized in the formulation of products. Oteracil API Price is not always fixed or binding as the Oteracil Price is obtained through a variety of data sources. The Oteracil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Oteracil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oteracil, including repackagers and relabelers. The FDA regulates Oteracil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oteracil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Oteracil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Oteracil supplier is an individual or a company that provides Oteracil active pharmaceutical ingredient (API) or Oteracil finished formulations upon request. The Oteracil suppliers may include Oteracil API manufacturers, exporters, distributors and traders.
click here to find a list of Oteracil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Oteracil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oteracil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oteracil GMP manufacturer or Oteracil GMP API supplier for your needs.
A Oteracil CoA (Certificate of Analysis) is a formal document that attests to Oteracil's compliance with Oteracil specifications and serves as a tool for batch-level quality control.
Oteracil CoA mostly includes findings from lab analyses of a specific batch. For each Oteracil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oteracil may be tested according to a variety of international standards, such as European Pharmacopoeia (Oteracil EP), Oteracil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oteracil USP).
